Results 61 to 70 of about 47,298 (270)

Remission of Myasthenia Gravis: Clinical, Electrophysiological and Immunological Studies [PDF]

open access: yes, 1993
1993-03The prognosis of 142 patients with myasthenia gravis (MG) was clinically investigated. Forty-nine (35%) had clinical remission (CR) and 23 (16%) good improvement (GI), while 70 (49%) remained in poor condition.
TAKEGAMI, TOSHIHIKO   +3 more
core   +1 more source

Myasthenia gravis

open access: yesThe Lancet, 2001
Myasthenia gravis is an autoimmune disorder mainly caused by antibodies to the muscle acetylcholine receptors (AChRs) at the neuromuscular junction. Loss of these receptors leads to a defect in neuromuscular transmission with muscle weakness and fatigue.
Vincent, A, Palace, J, Hilton-Jones, D
openaire   +2 more sources

Presynaptic Congenital Myasthenic Syndromes

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Presynaptic congenital myasthenic syndromes (CMS) encompass a large number of rare neurologic disorders caused by impaired release of acetylcholine (ACh) from motor nerve terminals. There are two main groups of presynaptic CMS: one in which the amount of ACh in synaptic vesicles (SV) is diminished and another in which the mechanism of synaptic
Ricardo A. Maselli
wiley   +1 more source

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

Miastenia gravis: perfil clínico de uma série de 20 casos. [PDF]

open access: yes, 2008
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Braga, Fernando Martins
core  

New treatments for myasthenia: a focus on antisense oligonucleotides [PDF]

open access: yes, 2013
Corrado Angelini,1 Sara Martignago,2 Michela Bisciglia21IRCCS S Camillo, Via Alberoni, Venice, Italy; 2Department of Neurosciences, University of Padova, Via Giustiniani 5, 35128, Padova, ItalyAbstract: Autoimmune myasthenia gravis (MG) is a ...
Bisciglia M   +5 more
core   +1 more source

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma

open access: yes
American Journal of Hematology, EarlyView.
Léa Ousset   +2 more
wiley   +1 more source

Muscle‐Specific Kinase Signaling and Its Therapeutic Potential

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT The function of the neuromuscular junction (NMJ) is compromised in many neuromuscular diseases (NMDs) such as autoimmune or congenital myasthenia gravis (MG), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and muscular dystrophies.
Stine Marie Jensen   +2 more
wiley   +1 more source

Bedside and laboratory diagnostic testing in myasthenia

open access: yes, 2022
Myasthenia gravis (MG) and congenital myasthenic syndromes (CMS) are a group of disorders with a well characterised autoimmune or genetic and neurophysiological basis.
Radunovic, Aleksandar   +5 more
core   +1 more source

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset [PDF]

open access: yes, 2020
[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).[Methods] This observational cross-sectional multicenter study was based on information in the neurologist-driven Spanish Registry of Neuromuscular ...
Sevilla, Teresa   +33 more
core   +1 more source

Home - About - Disclaimer - Privacy